2024-08-27
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
According to China Securities Journal, late at night on August 26, a message suddenly spread across various WeChat groups: “Dear guests of the Jiahui,According to the emergency notice from the CDC, all Pasteur influenza vaccines will be suspended from August 27 (Trivalent and quadrivalent) for vaccination.You can cancel your appointment and get a refund through the Jiahui Health APP-Vaccine Center."
immediately,There is news that the Pasteur influenza vaccine produced by Sanofi has been suspended.What exactly happened?
Image source: Visual China
On the morning of August 27, a reporter from the Daily Economic News calledI called Jiahui Medical customer service and they said the hospital had received a notification from the Shanghai Center for Disease Control and Prevention, but the specific reason was unknown.The hospital is still waiting for further notification from the Shanghai Municipal Center for Disease Control and Prevention.Currently, all hospitals in Shanghai have suspended the vaccination of all Pasteur influenza vaccines. Customers who have already received the vaccine need to wait for official news.
The person said that more people in southern China have received the Pasteur flu vaccine. In Shanghai, flu vaccinations began in mid-August, and more children have received the Pasteur flu vaccine.
In addition, the reporter contacted Sanofi, who said they would conduct internal communication and reply later. The reporter called the Shanghai Center for Disease Control and Prevention, but the Immunization Planning Department was unreachable. The reporter then called the Shanghai Changning District Center for Disease Control and Prevention, who said the notice was issued by the Shanghai Center for Disease Control and Prevention and that they still needed to consult the Shanghai Center for Disease Control and Prevention.
According to The Paper, on August 27, Sanofi responded that influenza vaccine products are highly complex. During the ongoing stability study, SanofiIt was observed that the potency (relevant reference data for the vaccine to produce the expected biological effect) of the influenza vaccines Valein and Valjarra during the 2024-2025 influenza season showed a downward trend.We expect that the efficacy of the vaccine may be affected before the end of the product's shelf life. As a precautionary measure, Sanofi has decided to temporarily suspend the supply and sale of these vaccines in China.
Sanofi said that the influenza vaccines Valeline and Valeja, which have been launched and circulated this year, have been approved for marketing, strictly abide by various laws and regulations, national drug standards and various statutory requirements, and meet the release standards. No signs or evidence of product safety and effectiveness being affected were found.The decision to temporarily suspend the supply and sale of these vaccines in China is merely a precautionary measure.
China News Service noted thatMany community hospitals have recently issued notices stating that the above vaccines are out of stock.Taiyi Health Service Center in Beilin District, Xi'an City, Shaanxi Province, said on the 26th that both the quadrivalent influenza virus split vaccine and the trivalent influenza virus split vaccine of Sanofi Pasteur were out of stock, while the quadrivalent influenza virus split vaccine of Beijing Sinovac and Hualan Biotechnology was in normal supply.
The official WeChat public account of Guangzhou Liwan District Qiaozhong Street Community Health Service Center posted a message on the morning of August 27, indicating that Sanofi Pasteur influenza vaccine (for children over 6 months old) was out of stock. According to its post on August 19, Sanofi Pasteur influenza vaccine (for children over 6 months old) was in sufficient supply at that time.
On the 22nd, the official WeChat public account of Daming Palace Pioneer Community Health Service Station in Weiyang District, Xi'an City, Shaanxi Province posted a message showing that Pasteur quadrivalent influenza vaccine (split for 6 months and above) had arrived. However, when China News Service called the service station for consultation in the morning of the 27th, the staff said that the above vaccine could no longer be administered, and the reason was not disclosed yet.
It is worth noting that there has been a precedent of recall of Pasteur influenza vaccine.
According to China Securities Journal, in April 2018, Shenzhen Sanofi Pasteur Biological Products Co., Ltd. reported that during routine monitoring, the company found that the potency of some batches of influenza virus split vaccines showed a downward trend, and proactively recalled the relevant batches of influenza virus split vaccines with a recall level of three.
According to the recall brief at the time, Sanofi Pasteur observed a downward trend in the potency of a specific batch of vaccines during routine quality follow-up inspections of the influenza virus split vaccine (Valenza I) produced in 2017. The relevant batches of Valenza R influenza vaccine are safe and effective and will not affect the immune effect and safety of vaccinated consumers. As a preventive measure, it was decided to proactively recall the relevant batches of Valenza R influenza vaccine. In accordance with the provisions of the "Drug Recall Management Measures", with the active cooperation of relevant CDCs and vaccination sites, the company has completed the proactive recall of all relevant batches of products.
Influenza vaccines have been approved for marketing in China, and the competition landscape is becoming increasingly fierce. According to statistics from Everbright Securities, as of the end of December 2023, 260 batches of quadrivalent influenza vaccines were issued in China throughout the year. Among them, Hualan Bio and the three major institutes ranked first with 88 batches issued, and Sinovac Biotech and Sanofi Pasteur ranked second and third with 41 batches and 25 batches issued, respectively.
According to the Drug Review Center of the National Medical Products Administration, since 2024, my country has added three entities that have applied for the marketing of new quadrivalent influenza vaccines, namely Chengdu Sinopilot, Olin Biopharmaceuticals, Lanzhou Bailing, Jiangsu Kangrun Biopharmaceuticals, and Shenzhen Kangtai Biopharmaceuticals.
On August 27, Sanofi China confirmed that as a preventive measure, the company decided to temporarily suspend the supply and sales of influenza vaccines in China.
On the morning of the 27th, The Paper contacted Hualan Vaccine, a domestic influenza vaccine manufacturer, as an investor. As for whether the company's influenza vaccine production capacity and batch release will be accelerated after Sanofi suspended vaccination, the staff said that these are all preparatory work. Now the company has issued many batches of influenza vaccines and has begun to supply the market. Some markets can be vaccinated, and the company's production volume can meet market demand.
In its reply, Sanofi mentioned that the company has observed that the potency of the influenza vaccines Valeline and Valeja in the 2024-2025 influenza season is showing a downward trend, and it is expected that the vaccine efficacy may be affected before the end of the product's validity period. Regarding the question of whether the effective price of Hualan Vaccine's influenza vaccine has been reduced, the above-mentioned staff member said that we do not have this problem. The China National Institute for Inspection and Quarantine will conduct quality control and quality assurance work on the products during batch issuance and vaccine companies.
In the early trading of A-shares today, vaccine stocks rose abnormally, Hualan Vaccine and Jindik hit the daily limit. Sinocell, Beike Bio, Lukang Pharmaceutical and others all rose.
The stock price of Hualan Biotechnology (SZ002007) also performed quite well. As of midday on August 27, Hualan Biotechnology reported 15.11 yuan, up 2.44%, with a market value of 27.63 billion yuan.
Daily Economic News Comprehensive Securities China, The Paper, China News Service, Daily Economic News (Reporter Lin Zichen), Public Information
Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. You will be responsible for your own risks if you act accordingly.
Daily Economic News
Collect and organize the latest news information and make it available for free for everyone to read
